COMMUNIQUÉS West-GlobeNewswire

CTD to Present at National Niemann-Pick Disease Foundation Annual Conference
27/06/2018
Conference brings together families affected by NPC from across the US ALACHUA, Fla., June 27, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB:CTDH), a clinical stage biotechnology company that develops cyclodextrin- [...]
Anthera Pharmaceuticals Announces Withdrawal of its Nasdaq Hearing Request and Suspension of Trading of its Securities on the NASDAQ Capital Markets
27/06/2018
HAYWARD, Calif., June 27, 2018 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) (“Anthera” or the “Company”) announced today that it has withdrawn its request for a hearing to appeal the delisting [...]
Progressive Care Inc. Signs New Investment Banking Agreement with The Benchmark Company, LLC
27/06/2018
MIAMI, June 27, 2018 (GLOBE NEWSWIRE) -- Progressive Care, Inc. (OTCQB:RXMD), a personalized healthcare services and technology company, today announced that it has engaged The Benchmark Company, LLC as a financial [...]
AVROBIO, Inc. Appoints Phillip B. Donenberg to its Board of Directors
27/06/2018
Industry leader brings expertise in finance, M&A and operations as former CFO of gene therapy company, AveXis, Inc. CAMBRIDGE, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- AVROBIO, Inc. (NASDAQ:AVRO), a Phase 2 clinical [...]
Advanced Bifurcation Selected to Join MaRS Venture Services
27/06/2018
Company Secures Trademark for ABS and ABS Mother-Daughter LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an [...]
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
27/06/2018
NORCROSS, Ga., June 27, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the [...]
Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103
27/06/2018
Top-line results expected early Q4 2018 REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on [...]
Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
27/06/2018
Phase 1/2 vaccine trial against the Middle East Respiratory Syndrome (MERS) will begin this summer in Korea; CEPI grant supports Inovio’s MERS vaccine through Phase 2 testing PLYMOUTH MEETING, Pa., June 27, 2018 (GLOBE [...]
PolarityTE Provides Update on Key Opinion Leader Event and Addresses Misleading Report
27/06/2018
SALT LAKE CITY, June 27, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (Nasdaq:COOL) today announced that the Company hosted a successful meeting of key opinion leaders in New York City on June 25, 2018, addressing the use [...]
Repligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands
27/06/2018
WALTHAM, Mass., June 27, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced an agreement with Navigo Proteins GmbH (“ [...]
GBT Announces Positive Top-line Data from Part A of the Phase 3 HOPE Study of Voxelotor in Sickle Cell Disease
27/06/2018
Primary Endpoint Achieved; 58 Percent of Patients on Voxelotor Dosed with 1500 mg at Week 12 Exceeded 1 g/dL Increase in Hemoglobin Versus 9 Percent of Placebo (p<0.0001) Company Met with FDA on June 25 and Is in [...]
Ritter Pharmaceuticals Announces Appointment of Andrew J. Ritter as Chief Executive Officer
27/06/2018
LOS ANGELES, June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to [...]
Summit Therapeutics Announces PhaseOut DMD Did Not Meet Primary Endpoint
27/06/2018
Summit Therapeutics plc ('Summit', or 'the Company') Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint Ezutromid Development to be Discontinued Summit to Focus on Advancing its Pipeline of New Mechanism [...]
BioPorto has finalized clinical studies enabling submission of the FDA application for The NGAL Test™ in July 2018
27/06/2018
June 27, 2018 Announcement no. 12 BioPorto A/S (“BioPorto”) has successfully completed clinical studies for The NGAL Test™ in collaboration with leading US hospitals. The data collected is being statistically processed [...]
Ritter Pharmaceuticals Initiates First Pivotal Phase 3 Trial for RP-G28 for the Treatment of Lactose Intolerance
27/06/2018
Conference Call Today - June 27, 2018 at 4:30 p.m. ET LOS ANGELES , June 27, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative [...]
Emerald Health Therapeutics Announces Amendment to Pure Sunfarms’ Cultivation License, Substantially Expanding Cannabis Production Area to 225,000 Square Feet
27/06/2018
VANCOUVER, British Columbia, June 27, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSX-V:EMH) (OTCQX:EMHTF) (“Emerald”) and Village Farms International, Inc. (“Village Farms” or the “Company”) (TSX:VFF) ( [...]
Loop Industries announces world’s first integrated waste to Loop™ PET resin manufacturing technology
27/06/2018
Revolutionary new manufacturing process will position Loop to commercialize its Generation II technology and disrupt how PET resin and polyester fiber is recycled and manufactured TERREBONNE, Quebec, June 27, 2018 ( [...]
Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery
27/06/2018
-I.V. CR845 achieved statistical significance for the study’s primary endpoint of pain relief over the 0 to 24-hour (AUC 0-24) period post-surgery for combined surgeries at the 1.0 mcg/kg dose (p=0.032)- -I.V. CR845 [...]
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis
27/06/2018
TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company") , a company focused on the research, development and commercialization of novel [...]

Pages